Daniel Jeffrey Moore Sells 1,000 Shares of LivaNova PLC (LIVN) Stock

Share on StockTwits

LivaNova PLC (NASDAQ:LIVN) Director Daniel Jeffrey Moore sold 1,000 shares of the firm’s stock in a transaction dated Monday, October 15th. The shares were sold at an average price of $113.30, for a total transaction of $113,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Daniel Jeffrey Moore also recently made the following trade(s):

  • On Monday, September 17th, Daniel Jeffrey Moore sold 1,000 shares of LivaNova stock. The shares were sold at an average price of $123.49, for a total transaction of $123,490.00.
  • On Wednesday, August 15th, Daniel Jeffrey Moore sold 1,000 shares of LivaNova stock. The shares were sold at an average price of $121.58, for a total transaction of $121,580.00.

LIVN opened at $113.59 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.08 and a current ratio of 1.51. LivaNova PLC has a 1-year low of $72.30 and a 1-year high of $131.54. The company has a market capitalization of $5.65 billion, a price-to-earnings ratio of 33.71, a price-to-earnings-growth ratio of 3.41 and a beta of 0.95.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, August 1st. The company reported $0.96 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.92 by $0.04. LivaNova had a negative net margin of 4.93% and a positive return on equity of 9.24%. The business had revenue of $287.50 million for the quarter, compared to analyst estimates of $278.08 million. During the same period last year, the company posted $0.93 EPS. The business’s revenue was up 12.4% on a year-over-year basis. Sell-side analysts forecast that LivaNova PLC will post 3.18 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its stake in LivaNova by 6.1% in the 2nd quarter. BlackRock Inc. now owns 5,393,015 shares of the company’s stock worth $538,332,000 after purchasing an additional 309,138 shares in the last quarter. FMR LLC lifted its stake in LivaNova by 0.3% in the 2nd quarter. FMR LLC now owns 4,843,407 shares of the company’s stock worth $483,469,000 after purchasing an additional 13,847 shares in the last quarter. OppenheimerFunds Inc. lifted its stake in LivaNova by 5.9% in the 2nd quarter. OppenheimerFunds Inc. now owns 1,279,827 shares of the company’s stock worth $127,752,000 after purchasing an additional 71,806 shares in the last quarter. Wells Fargo & Company MN lifted its stake in LivaNova by 31.4% in the 2nd quarter. Wells Fargo & Company MN now owns 1,177,233 shares of the company’s stock worth $117,511,000 after purchasing an additional 281,610 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in LivaNova by 5.3% in the 2nd quarter. Northern Trust Corp now owns 727,634 shares of the company’s stock worth $72,632,000 after purchasing an additional 36,622 shares in the last quarter. 86.95% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages recently weighed in on LIVN. ValuEngine raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, June 27th. Needham & Company LLC reaffirmed a “buy” rating and issued a $135.00 price target (up from $128.00) on shares of LivaNova in a research note on Wednesday, August 1st. BidaskClub lowered shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 12th. Zacks Investment Research raised shares of LivaNova from a “sell” rating to a “hold” rating in a research note on Wednesday, July 4th. Finally, Jefferies Financial Group raised their price target on shares of LivaNova to $150.00 and gave the company a “buy” rating in a research note on Tuesday, October 2nd. Three research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. LivaNova currently has an average rating of “Buy” and a consensus target price of $113.33.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.

Recommended Story: Marijuana Stocks Future Looks Bright

Insider Buying and Selling by Quarter for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply